15 June 2015
EMA/PDCO/351567/2015
Procedure Management and Committees Support Division

Paediatric Committee (PDCO)

Draft agenda for the meeting on 17-19 June 2015

Chair: Dirk Mentzer – Vice-Chair: Koenraad Norga

17 June 2015, 08:30- 19:00, room 3A

18 June 2015, 08:30- 19:00, room 3A

19 June 2015, 08:30- 13:00, room 3A

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued).

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

Table of contents

1. Introductions 4

1.1. Welcome and declarations of interest of members, alternates and experts 4

1.2. Adoption of agenda 4

1.3. Adoption of the minutes 4

2. Opinions 4

2.1. Opinions on Products 4

2.2. Opinions on Compliance Check 4

2.3. Opinions on Modification of an Agreed Paediatric Investigation Plan 4

2.4. Opinions on Re-examinations 4

2.5. Finalisation and adoption of opinions 4

3. Discussion of applications 4

3.1. Discussions on Products D90-D60-D30 5

3.2. Discussions on Compliance Check 5

3.3. Discussions on Modification of an Agreed Paediatric Investigation Plan 5

4. Nominations 5

4.1. List of letters of intent received for submission of applications with start of procedure June 2015 for Nomination of Rapporteur and Peer reviewer 5

4.2. Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver. 5

4.3. Nominations for other activities 5

4.3.1. Re-nomination of two PDCO representatives to the Paediatric Formulary Group of the European Pharmacopoeia: Professor Anthony Nunn and Doctor Siri Wang 5

4.3.2. List of EMA activities requiring the nomination of PDCO experts 5

5. Scientific Advice Working Party (SAWP) and Paediatric Committee (PDCO) Interaction 6

5.1. Discussions on first reports of SAWP products with paediatric interest 6

5.2. Discussions on SAWP products following a discussion meeting with companies 6

6. Discussion on the applicability of class waivers 6

6.1. Discussions on the applicability of class waiver for products 6

7. Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver 6

7.1. Discussion on the possibility to include an indication within a condition in an agreed PIP/waiver 6

8. Annual reports on deferrals 6

8.1.1. Rituximab – MabThera – EMEA-000308-PIP01-08 6

8.1.2. Rituximab – MabThera – EMEA-000308-PIP02-11 7

8.1.3. Artemether (20mg) and lumefantrine (120mg) – RIAMET (in all EU), Coartem in some countries such as US, Switzerland, Australia, African countries...- EMEA-000777-PIP01-09 . 7

8.1.4. Denosumab – XGEVA (previously Amgiva), Prolia – EMEA-000145-PIP01-07 7

8.1.5. Denosumab – XGEVA (previously Amgiva), Prolia – EMEA-000145-PIP02-12 7

8.1.6. Aripiprazole – Abilify – EMEA-000235-PIP02-10 7

8.1.7. Icatibant acetate – Firazyr – EMEA-000408-PIP01-08 – Orphan 7

9. Organisational, regulatory and methodological matters 8

9.1. Mandate and organisation of the PDCO 8

9.1.1. Review of PDCO meeting agenda (feedback from Strategic Review and Learning Meeting in Frankfurt 28-29 May 2015) 8

9.1.2. Communication of PDCO activities/outcomes to the public (feedback from Strategic Review and Learning Meeting in Frankfurt 28-29 May 2015) 8

9.1.3. Full waivers for fixed-dose combination for antihypertensive drugs 8

9.2. Coordination with EMA Scientific Committees or CMDh-v 8

9.2.1. Committee for Medicinal Products for Human Use (CHMP) 8

9.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups 8

9.3.1. Non-clinical Working Group: D30 Products identified 8

9.3.2. Formulation Working Group: D30 Products identified 8

9.3.3. Paediatric Investigation Plan for DTaP-containing combination vaccine 8

9.4. Cooperation within the EU regulatory network 9

9.5. Cooperation with International Regulators 9

9.6. Contacts of the PDCO with external parties and interaction with the Interested Parties to the Committee 9

9.7. PDCO work plan 9

9.8. Planning and reporting 9

9.9. PDCO ORGAM 9

10. Any other business 9

10.1. EMA 20th anniversary event on innovation and early dialogue with experts and staff 9

11. Breakout sessions 9

11.1.1. Paediatric oncology 9

11.1.2. Neonatology 9

11.1.3. Inventory 10

Explanatory notes 11

1. Introductions

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the PDCO plenary session to be held 17-19 June 2015. See June 2015 PDCO minutes (to be published post July 2015 PDCO meeting).

1.2. Adoption of agenda

PDCO agenda for 17-19 June 2015.

1.3. Adoption of the minutes

PDCO minutes for 20-22 May 2015.

2. Opinions

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

2.1. Opinions on Products

2.2. Opinions on Compliance Check

The following compliance checks have been put up for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance.

2.3. Opinions on Modification of an Agreed Paediatric Investigation Plan

2.4. Opinions on Re-examinations

2.5. Finalisation and adoption of opinions

3. Discussion of applications

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Discussions on Products D90-D60-D30

3.2. Discussions on Compliance Check

The following compliance checks have been put up for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance

3.3. Discussions on Modification of an Agreed Paediatric Investigation Plan

4. Nominations

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

4.1. List of letters of intent received for submission of applications with start of procedure June 2015 for Nomination of Rapporteur and Peer reviewer

Action: For adoption

4.2. Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver.

Action: For adoption

4.3. Nominations for other activities

4.3.1. Re-nomination of two PDCO representatives to the Paediatric Formulary Group of the European Pharmacopoeia: Professor Anthony Nunn and Doctor Siri Wang

Action: For adoption

4.3.2. List of EMA activities requiring the nomination of PDCO experts

Action: For adoption

5. Scientific Advice Working Party (SAWP) and Paediatric Committee (PDCO) Interaction

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. Discussions on first reports of SAWP products with paediatric interest

5.2. Discussions on SAWP products following a discussion meeting with companies

6. Discussion on the applicability of class waivers

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Discussions on the applicability of class waiver for products

7. Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver

7.1. Discussion on the possibility to include an indication within a condition in an agreed PIP/waiver

No requests were received for the month of June.

8. Annual reports on deferrals

8.1.1. Rituximab – MabThera – EMEA-000308-PIP01-08

Roche Registration Ltd

Difficulties progressing the PIP? Yes

Action: For information

8.1.2. Rituximab – MabThera – EMEA-000308-PIP02-11

Roche Registration Ltd

Difficulties progressing the PIP? No

Action: For information

8.1.3. Artemether (20mg) and lumefantrine (120mg) – RIAMET (in all EU), Coartem in some countries such as US, Switzerland, Australia, African countries...- EMEA-000777-PIP01-09

Novartis Europharm Limited

Difficulties progressing the PIP? Yes

Action: For information

8.1.4. Denosumab – XGEVA (previously Amgiva), Prolia – EMEA-000145-PIP01-07

Amgen Europe B.V.

Difficulties progressing the PIP? No

Action: For information

8.1.5. Denosumab – XGEVA (previously Amgiva), Prolia – EMEA-000145-PIP02-12

Amgen Europe B.V.

Difficulties progressing the PIP? No

Action: For information

8.1.6. Aripiprazole – Abilify – EMEA-000235-PIP02-10

Otsuka Pharmaceutical Europe Ltd.

Difficulties progressing the PIP? No

Action: For information

8.1.7. Icatibant acetate – Firazyr – EMEA-000408-PIP01-08 – Orphan

Jerini AG

Difficulties progressing the PIP? No

Action: For information

9. Organisational, regulatory and methodological matters

9.1. Mandate and organisation of the PDCO

9.1.1. Review of PDCO meeting agenda (feedback from Strategic Review and Learning Meeting in Frankfurt 28-29 May 2015)

PDCO member: Dirk Mentzer

Action: For discussion

9.1.2. Communication of PDCO activities/outcomes to the public (feedback from Strategic Review and Learning Meeting in Frankfurt 28-29 May 2015)

PDCO member: Koenraad Norga

Action: For discussion

9.1.3. Full waivers for fixed-dose combination for antihypertensive drugs

Action: For discussion

9.2. Coordination with EMA Scientific Committees or CMDh-v

9.2.1. Committee for Medicinal Products for Human Use (CHMP)

Action: For information

9.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

9.3.1. Non-clinical Working Group: D30 Products identified

PDCO member: Jacqueline Carleer

Action: For information

9.3.2. Formulation Working Group: D30 Products identified

PDCO member: Brian Aylward

Action: For information

9.3.3. Paediatric Investigation Plan for DTaP-containing combination vaccine

PDCO member: Marta Granström

Action: For adoption

9.4. Cooperation within the EU regulatory network

None

9.5. Cooperation with International Regulators

None

9.6. Contacts of the PDCO with external parties and interaction with the Interested Parties to the Committee

None

9.7. PDCO work plan

None

9.8. Planning and reporting

None

9.9. PDCO ORGAM

None

10. Any other business

10.1. EMA 20th anniversary event on innovation and early dialogue with experts and staff

Wednesday 17 June 2015, 13:00-14:00, Promenade lounge (-1)

11. Breakout sessions

11.1.1. Paediatric oncology

Action: For discussion on Thursday, 18:00 - 19:00, room 3M

11.1.2. Neonatology

Action: For discussion on Thursday, 18:00 - 19:00, room 3L

11.1.3. Inventory

Action: For discussion on Thursday, 18:00 - 19:00, room 3H

Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Paediatric investigation plan (PIP) (section 2.1 Opinion on PIPs and section 3.1 Discussions on PIPs)
A paediatric investigation plan (PIP) is a development plan aimed at ensuring that the necessary data are obtained through studies in children, when it is safe to do so, to support the authorisation of a medicine for children. Pharmaceutical companies submit proposals for PIPs to the European Medicines Agency's Paediatric Committee (PDCO). This Committee is responsible for agreeing or refusing the plan.

Compliance checks (section 2.2 Opinions on Compliance check, section 3.2 Discussions on Compliance check)
A compliance check may be necessary before any application for marketing authorisation (even for an adult indication) can be considered valid, if there was no deferral for at least one of the studies agreed in the PIP, or after the due date of initiation or completion of a study/measure. The same applies to some regulatory applications for authorised products, as described above.

Modification of an Agreed Paediatric Investigation Plan (section 2.3 Opinions on Modification of an agreed PIP, section 3.3 Discussions on Modification of an agreed PIP)
The development plan for a medicine can be modified at a later stage as knowledge increases. Modifications can also be made if the applicant encounters such difficulties with the implementation of a PIP, which render it unworkable or no longer appropriate.
In some cases, studies can be deferred until after the studies in adults have been conducted. This ensures that research in children is done only when it is safe and ethical to do so. Even when studies are deferred, the PIP will include details of the paediatric studies and their timelines.

Class waiver (section 6 Discussion on the applicability of class waiver)
As some diseases do not affect children (for example Parkinson's disease), the development of medicines for these diseases should not be performed in children. In these cases, a PIP is not required and it will be waived**.** For more information on the classes of diseases subject to waivers, see class waivers.

Annual reports on deferrals (section 8)
If the medicinal product is approved in the EU, annual reports on the deferred measures in the PIP must be submitted to the Agency.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/